Meetings and Studies

July 2015 in “ Hair transplant forum international ”

Henrique N. Radwanski, Mario Marzola

Studysummary This article summarizes the events and discussions from the 4th Scientific Meeting of the Asian Association of Hair Restoration Surgeons held in Bangkok, reporting no new research findings.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Read the full study on ishrs-htforum.org →

Discuss this study in the Community →

Similar research 5

Meetings and Studies: Review of the 24th World Congress of the International Society of Hair Restoration Surgery Hair transplant forum international · 2016
Meetings and Studies: Review of the 2nd ABCRC FUE Workshop October 16-17, 2015, Goiânia, Brazil Hair transplant forum international · 2016
Review of the 23rd Annual Scientific Meeting of the International Society of Hair Restoration Surgery, September 9-13, 2015, Chicago, Illinois, USA Hair transplant forum international · 2015
Meetings and Studies: Review of the 3rd Mediterranean FUE Workshop June 25-27, 2015, Istanbul, Turkey Hair transplant forum international · 2015
Meetings and Studies: Review of the 22nd Annual Scientific Meeting of the International Society of Hair Restoration Surgery, October 8-11, 2014, Kuala Lumpur, Malaysia Hair transplant forum international · 2015

Related Community Posts Join

6 / 125 results

community Do you believe these studies are real or just fear mongering

in Finasteride/Dutasteride 157 upvotes 11 months ago

Finasteride can regrow hair but may cause depression and suicidal thoughts in some users. The connection between finasteride and mental health issues is debated, with some attributing it to pre-existing conditions or stress.

community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march

30 upvotes 6 months ago

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026

122 upvotes 6 months ago

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

community Oral minoxidl - Is this a medication that's generally safe to take for life? Like what I understand oral fin is? Also do studies show that in general or in a significant amount of more cases that results with oral minox + oral fin > oral fin in terms of long-term use(talkin 20+ years).

in Minoxidil 77 upvotes 1 year ago

Oral minoxidil combined with finasteride can improve hair density, but long-term safety is uncertain due to potential side effects like heart and kidney issues. Users report mixed experiences, with some experiencing side effects and others finding it effective for hair maintenance.

community Efficacy of Dut at 0.5mg VS 1mg VS 2.5mg

in Finasteride/Dutasteride 49 upvotes 1 year ago

Higher doses of dutasteride, such as 2.5mg, are more effective at reducing scalp DHT than 0.5mg, but are costly and inconvenient. A 1mg dose is considered a more affordable and practical option, though its efficacy is uncertain.

community US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?

13 upvotes 7 months ago

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.